Home Cart 0 Sign in  

[ CAS No. 130878-68-1 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 130878-68-1
Chemical Structure| 130878-68-1
Structure of 130878-68-1 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 130878-68-1 ]

Related Doc. of [ 130878-68-1 ]

Alternatived Products of [ 130878-68-1 ]

Product Details of [ 130878-68-1 ]

CAS No. :130878-68-1 MDL No. :MFCD00153370
Formula : C24H24N2O6 Boiling Point : -
Linear Structure Formula :- InChI Key :JPJMNCROLRPFHI-QFIPXVFZSA-N
M.W : 436.46 Pubchem ID :11339559
Synonyms :
Chemical Name :Fmoc-Val-OSu

Calculated chemistry of [ 130878-68-1 ]

Physicochemical Properties

Num. heavy atoms : 32
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.33
Num. rotatable bonds : 9
Num. H-bond acceptors : 6.0
Num. H-bond donors : 1.0
Molar Refractivity : 118.62
TPSA : 102.01 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : No
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -6.51 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.03
Log Po/w (XLOGP3) : 3.46
Log Po/w (WLOGP) : 2.78
Log Po/w (MLOGP) : 2.72
Log Po/w (SILICOS-IT) : 2.96
Consensus Log Po/w : 2.99

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.41
Solubility : 0.017 mg/ml ; 0.000039 mol/l
Class : Moderately soluble
Log S (Ali) : -5.28
Solubility : 0.00227 mg/ml ; 0.0000052 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -5.77
Solubility : 0.000734 mg/ml ; 0.00000168 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 4.32

Safety of [ 130878-68-1 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 130878-68-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 130878-68-1 ]
  • Downstream synthetic route of [ 130878-68-1 ]

[ 130878-68-1 ] Synthesis Path-Upstream   1~11

  • 1
  • [ 6066-82-6 ]
  • [ 68858-20-8 ]
  • [ 130878-68-1 ]
YieldReaction ConditionsOperation in experiment
89% With dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 3 h; Dicyclocarbodiimide (1 .55 g, 7.52 mmol) and N-hydroxysuccinimide (762 mg, 6.63 mmol) are added at room temperature to a stirrer solution of Fmoc-Val-OH [9] (1 .5 g, 4.42 mmol) in anhydrous dichloromethane (25 ml_). The mixture is kept at room temperature for 3 hours. The white solid formed in this reaction is filtrated with dichloromethane to remove the dicyclohexylurea, the organic phase is washed with HCI 0.1 N and water, then dried over anhydrous sodium sulfate and the solvent removed by rotatory evaporation. The residue is subjected to a flash column chromatography in 1 percent methanol in dichloromethane to afford product [10] as a white solid, 1 .7 g (89percent yield). MS: m/z 459 [M+Na]+.1H NMR (400 MHz, CDCIs) δ 7.80 (d, J = 7.5 Hz, 2H), 7.68 - 7.55 (m, 2H), 7.43 (t, J = 7.4 Hz, 2H), 7.34 (dd, J = 15.9, 8.5 Hz, 2H), 4.70 (d, J = 4.6 Hz, 1 H), 4.56 - 4.40 (m, 3H), 4.28 (t, J = 6.6 Hz, 1 H), 2.85 (s, 4H), 2.37 (dd, J = 12.3, 6.5 Hz, 1 H), 1 .08 (dd, J = 1 1 .0, 6.9 Hz, 6H).
65% With dicyclohexyl-carbodiimide In 1,2-dimethoxyethane at 20℃; for 23 h; Cooling with ice; Inert atmosphere Fmoc-Valine (1.02 g, 3 mmol) and N-hydroxysuccinimide (0.345 g, 3 mmol) were dissolved in dimethoxy ethane (35 ml) and cooled in an ice bath, then DCC (0.681 g, 3.3 mmol) was added. The resulting mixture was stirred in the ice bath for 3 hours, then at room temperature for 20 hours. The precipitate formed was filtered off and the filtrate concentrated under vacuo. The crude product was further purified by flash chromatography (ethyl acetate/hexane, v:v, 4:6) to afford SI20B as a white solid. Isolated yield: 65percent. TLC (EtOAc:Hexane 3:2). Rf=0.57, irradiated by a UV lamp. HPLC: 0.1percent TFA (v/v) in water (solvent A):acetonitrile (solvent B); gradient 45-85percent in 30 min, flow rate=0.5 mL/min. Retention time (Rt)=15.77 min. 1H NMR (FIG. 26A): (400 MHz, CDCl3) δ 7.76-7.78 (d, J=7.20 Hz, 2H), 7.59-7.60 (d, J=7.20 Hz, 2H), 7.38-7.42 (t, J=7.20 Hz, 2H), 7.30-7.34 (m, 2H), 5.26-5.28 (d, J=9.20 Hz, 1H), 4.67-4.71 (dd, J=4.8, 5.2 Hz, 1H), 4.42-4.46 (dd, J=6.8, 6.4 Hz, 2H), 4.23-4.26 (t, J=6.8 Hz, 1H), 2.84 (s, 4H), 2.04-2.36 (m, 1H), 0.83-088 (m, 6H). 13C NMR (FIG. 26B): (101 MHz, CDCl3) δ 168.7, 141.5, 127.9, 127.3, 127.3, 125.3, 120.2, 120.2, 67.5, 57.7, 47.4, 31.9, 25.8, 18.9, 17.5.
26.51 g With dicyclohexyl-carbodiimide In tetrahydrofuran at 0 - 20℃; for 6 h; Inert atmosphere [00125] This compound is prepared according to R. A. Firestone et al, US 6,214,345. Fmoc-Val-OH (20.24 g; 59.64 mmol) and N-hydroxysuccinimide (6.86 g =1 .0 eq.) in tetrahydrofuran (200 ml) at 000 were treated with N,N’dicyclohexylcarbodiimide (12.30 g; 1.0 eq.). The mixture was stirred at RT under argon atmosphere for 6 h and then the solid dicyclohexyl urea (DCU) by-product was filtered off and washed with THF and the solvent was removed by rotavap. The residue was dissolved in 300 ml dichloromethane, cooled in an ice bath for 1 h and filtered again to remove additional DCU. The dichloromethane was evaporated and the solid foam (26.51 g) was used in the next step without further purification.
Reference: [1] Journal of Pharmaceutical Sciences, 1994, vol. 83, # 7, p. 999 - 1005
[2] Langmuir, 2010, vol. 26, # 7, p. 4990 - 4998
[3] Patent: WO2018/178060, 2018, A1, . Location in patent: Page/Page column 64-66
[4] Journal of the American Chemical Society, 2015, vol. 137, # 21, p. 6932 - 6940
[5] Patent: US2017/247324, 2017, A1, . Location in patent: Paragraph 0284; 0285
[6] Tetrahedron, 2009, vol. 65, # 19, p. 3871 - 3877
[7] Organic and Biomolecular Chemistry, 2011, vol. 9, # 11, p. 4182 - 4187
[8] Journal of Controlled Release, 2012, vol. 160, # 3, p. 618 - 629
[9] Patent: WO2013/67597, 2013, A1, . Location in patent: Page/Page column 80
[10] Patent: WO2014/80251, 2014, A1, . Location in patent: Sheet 16/23
[11] Patent: WO2015/21092, 2015, A1, . Location in patent: Page/Page column 36
[12] Bioconjugate Chemistry, 2015, vol. 26, # 11, p. 2261 - 2278
[13] Patent: WO2017/149077, 2017, A1, . Location in patent: Paragraph 00128-00129
[14] Patent: CN107789630, 2018, A, . Location in patent: Paragraph 0067; 0068; 0069
[15] Patent: WO2018/115466, 2018, A1, . Location in patent: Paragraph 00103; 00124; 00125
  • 2
  • [ 68858-20-8 ]
  • [ 130878-68-1 ]
Reference: [1] Tetrahedron Letters, 2002, vol. 43, # 9, p. 1661 - 1664
  • 3
  • [ 68858-20-8 ]
  • [ 130878-68-1 ]
Reference: [1] Patent: US6759509, 2004, B1,
  • 4
  • [ 130878-68-1 ]
  • [ 160885-98-3 ]
Reference: [1] Organic and Biomolecular Chemistry, 2011, vol. 9, # 11, p. 4182 - 4187
  • 5
  • [ 1037794-22-1 ]
  • [ 130878-68-1 ]
  • [ 159858-22-7 ]
Reference: [1] Journal of Medicinal Chemistry, 2018, vol. 61, # 3, p. 989 - 1000
[2] Patent: WO2015/95227, 2015, A2, . Location in patent: Page/Page column 144
[3] Patent: WO2017/66668, 2017, A1, . Location in patent: Paragraph 000160
  • 6
  • [ 130878-68-1 ]
  • [ 159858-22-7 ]
Reference: [1] Journal of Controlled Release, 2012, vol. 160, # 3, p. 618 - 629
[2] Patent: WO2014/80251, 2014, A1,
[3] Patent: WO2017/66668, 2017, A1,
[4] Patent: KR2017/41562, 2017, A,
[5] Patent: CN107789630, 2018, A,
  • 7
  • [ 56-41-7 ]
  • [ 130878-68-1 ]
  • [ 150114-97-9 ]
YieldReaction ConditionsOperation in experiment
85% With sodium hydrogencarbonate In tetrahydrofuran; water at 20℃; 2.0 g of Fmoc-Val-OSu (4.58 mmol, 1 eq) diluted in 10 mL THF was added to a solution of 0.43 g H-Ala-OH (4.81 mmol, 1.05 eq) and a solution of 0.40 g NaHCO3 (4.81 mmol, 1.05 eq) dissolved in 15 mL H2O. Immediately, the colorless solution turned turbid. A mixture of H2O, THF and diethyl ether (60 mL, 1:1:1) was added until a clear solution resulted. The solution was stirred well at room temperature. After a week the solvents were removed under reduced pressure and 30 mL citric acid (15percent aqueous) and 50 mL ethyl acetate were added and the mixture was stirred for one hour at room temperature. The phases were separated and the aqueous layer was extracted three times (3×100 mL) with ethyl acetate. The combined organic phases were dried, and the solvent was evaporated. Afterwards, the residue was purified by flash chromatography on silica gel (CHCl3/MeOH 30:1+1percent AcOH) to give a colorless solid (1.60 g, 85percent). 1H NMR (DMSO-d6): δ[ppm] 0.87 (d, 3H, J=6.8 Hz), 0.90 (d, 3H, J=6.8 Hz), 1.27 (d, 3H, J=7.3 Hz), 1.94-2.06 (m, 1H), 3.90 (t, 1H, J=7.2 Hz), 4.17-4.31 (m, 4H), 7.30-7.35 (m, 2H), 7.39-7.44 (m, 3H), 7.76 (t, 2H, J=6.6 Hz), 7.89 (d, 2H, J=7.5 Hz), 8.22 (d, 1H, J=6.9 Hz), 12.50 (bs, 1H). 13C NMR (DMSO-d6): δ[ppm] 17.5, 18.6, 19.6, 30.9, 47.1, 47.9, 60.2, 66.1, 120.5, 125.8, 127.5, 128.1, 141.1, 144.2, 144.3, 156.5, 171.4, 174.4.
74% With sodium hydrogencarbonate In tetrahydrofuran; water at 20℃; for 50 h; Step 2 product is prepared in analogy to P.W. Howard et al. US 2011/0256157. A solution of L-alanine (5.58 g; 1.05 eq.) and sodium hydrogen carbonate (5.51 g; 1.1 eq.) in 150 ml water was prepared and added to a solution of HOP 30.1343 (26.51 g; max. 59.6 mmol) in 225 ml tetrahydrofuran. The mixture was stirred for 50 h at RT. After consumption of starting material the solution was partitioned between 240 ml of 0.2 M citric acid and 200 ml of ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate (3 x 200 ml). The combined organic layers were washed with water and brine (300 ml each) dried (Mg504) and the solvent was evaporated to approx. 200 ml. Pure product precipitated at this time and was filtered off. The mother liquor was evaporated to dryness and the residue was stirred 1 h with 100 ml MTBE to result additional crystalline material. The two crops of product were combined to 18.01 g (74percent) white powder. (m.p.: 203-207°C)
18.01 g With sodium hydrogencarbonate In tetrahydrofuran; water at 20℃; for 50 h; product is prepared in analogy to P.W. Howard et al. US 2011/0256157. A solution of L-alanine (5.58 g; 1.05 eq.) and sodium hydrogen carbonate (5.51 g; 1.1 eq.) in 150 ml water was prepared and added to a solution of HDP 30.1343 (26.51 g; max. 59.6 mmol) in 225 ml tetrahydrofuran. The mixture was stirred for 50 h at RT. After consumption of starting material the solution was partitioned between 240 ml of 0.2 M citric acid and 200 ml of ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate (3 x 200 ml). The combined organic layers were washed with water and brine (300 ml each) dried (MgS04) and the solvent was evaporated to approx. 200 ml. Pure product precipitated at this time and was filtered off. The mother liquor was evaporated to dryness and the residue was stirred 1 h with 100 ml MTBE to result additional crystalline material. The two crops of product were combined to 18.01 g (74percent) white powder, (m.p.: 203-207X) [ +Naf found: 410.94; calc: 41 1.19 (C23H27N2O5) [M+Naf found: 433.14; calc: 433.17 (C23H27N2O5) [2M+H]+ found: 842.70; calc: 843.36 (C46H52N4NaO10)
Reference: [1] Journal of Medicinal Chemistry, 2012, vol. 55, # 17, p. 7502 - 7515
[2] Patent: US2014/51623, 2014, A1, . Location in patent: Paragraph 0063-0066
[3] Patent: WO2018/115466, 2018, A1, . Location in patent: Paragraph 00103; 00124; 00126
[4] Patent: WO2017/149077, 2017, A1, . Location in patent: Paragraph 00130
  • 8
  • [ 130878-68-1 ]
  • [ 150114-97-9 ]
Reference: [1] Patent: US2014/363454, 2014, A1,
  • 9
  • [ 130878-68-1 ]
  • [ 159857-81-5 ]
Reference: [1] Patent: WO2017/66668, 2017, A1,
[2] Patent: WO2017/66668, 2017, A1,
[3] Patent: WO2017/66668, 2017, A1,
[4] Patent: WO2017/66668, 2017, A1,
[5] Patent: CN107789630, 2018, A,
[6] Patent: CN108743968, 2018, A,
  • 10
  • [ 130878-68-1 ]
  • [ 159857-79-1 ]
Reference: [1] Patent: WO2014/80251, 2014, A1,
[2] Patent: WO2015/95227, 2015, A2,
[3] Patent: WO2017/66668, 2017, A1,
[4] Patent: WO2017/66668, 2017, A1,
[5] Patent: CN107789630, 2018, A,
[6] Patent: WO2018/178060, 2018, A1,
[7] Patent: CN108743968, 2018, A,
  • 11
  • [ 130878-68-1 ]
  • [ 863971-53-3 ]
Reference: [1] Journal of Controlled Release, 2012, vol. 160, # 3, p. 618 - 629
[2] Patent: KR2017/41562, 2017, A,
Same Skeleton Products
Historical Records